Masimo (MASI) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Masimo

NasdaqGM•Healthcare•Medical Devices

--Market closed

Masimo Corporation engages in the development, manufacture, and marketing of various patient monitoring technologies, and automation and connectivity solutions worldwide. It offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo Rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of oxygen, carboxyhemoglobin, and methemoglobin. It also provides brain function and hemodynamic monitoring solutions; patient position and activity tracking, and neuromodulation technology solutions; and Masimo Hospital Automation platform, including hospital automation solutions, including Patient SafetyNet, Iris, iSirona, Replica, and UniView; and brain function monitoring, hemodynamic monitoring, regional oximetry, acoustic respiration rate monitoring, capnography and gas monitoring, and telehealth solutions. In addition, the company provides its products through direct sales force, distributors, and original equipment manufacturers partners to hospitals, emergency medical service and home care providers, long-term care facilities, physician offices, veterinarians, and consumers. Masimo Corporation was incorporated in 1989 and is headquartered in Irvine, California.

How this company scores

GoodMetricSide Score: 72/100

Strongest: Cash & Earnings Quality (23/25); weakest: Growth (11/25).

Profitability18/25

Growth11/25

Balance Sheet & Red Flags20/25

Cash & Earnings Quality23/25

Strengths

Rising free cash flowStrong marginsRising earningsInterest easily covered

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Watch

FCF/Net Income has dropped below 0.7x in 3 quarters — monitor for earnings quality deterioration.

Price & Volume

Metrics at a Glance

as of April 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $1.56B
Q. Revenue: $403.60M
TTM EBITDA: $347.70M
TTM Op. Income: $309.40M
Q. Op. Income: $77.40M
TTM Net Income: $76.30M
Q. Net Income: $57.10M
EPS: $1.1
Shares Out.: $52.20M

$1.56B in TTM revenue declined 21.0% YoY, reaching $403.60M last quarter. TTM EBITDA of $347.70M and TTM operating income of $309.40M show growth is flowing through to the bottom line. TTM net income of $76.30M means revenue is converting into profit. Over the past year, TTM revenue is down 21% — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 62.1%
EBITDA Margin: 21.2%
Op. Margin: 19.2%
Net Margin: 14.1%

Op. margin of 19.2% is down 1.8% YoY — costs are rising relative to revenue. Net margin at 14.1% and gross margin of 62.1% show how much of each revenue dollar survives to profit. Across the last 8 quarters, operating margin has fallen for 2 consecutive quarters — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: N/A
P/B Ratio: N/A

P/S of 0.0x and P/B of 0.0x.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $1.64B
Cash: $124.60M
Long-Term Debt: $445.70M
Book Value: $788.90M
D/E Ratio: 0.6
Debt/EBITDA: 5.2

With $1.64B in assets and $445.70M in long-term debt, D/E is 0.6and book value is $788.90M — a conservative capital structure with a cushion to weather downturns. Over the past year, debt/equity is down 16% — an improving trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $45.30M
TTM Free Cash Flow: $210.90M
FCF Margin: 13.5%
FCF / Net Income: 2.8

TTM FCF of $210.90M on $45.30M in operating cash flow. The FCF / Net Income ratio of 2.8x means free cash flow covers net income — earnings are backed by cash. Over the past year, free cash flow is up 26% — an improving trend.